Bernstein SocGen lowers BioMarin stock price target on guidance update By Investing.com

BioMarin reported Q1 2026 revenue of $766 million, beating estimates by 1% and EPS of $0.76 versus $0.74 expected, though EPS missed by 13% on a one-time COGS item. Bernstein SocGen cut its price target to $82 from $94 while keeping an Outperform rating, and Evercore ISI raised its target to $120 from $110. Management updated guidance to include Amicus-related contributions, implying 20% year-over-year revenue growth at the company level versus 5% on a standalone basis.

Analysis

BioMarin’s print is less about the quarter itself and more about the market re-rating math: when a high-multiple biotech misses on EPS but guides revenue up, the street usually splits into two camps — quality-growth buyers who focus on recurring top-line visibility, and valuation-sensitive holders who use any miss to de-risk. That creates a window where the stock can drift even as fundamentals improve, because the near-term debate shifts from execution to whether the current multiple is being underwritten by durable growth or just a temporary mix benefit.

The second-order effect is on the enzyme-replacement complex broadly. If BioMarin’s updated outlook is being boosted by deal-related contribution rather than purely organic acceleration, peers with cleaner standalone growth and less integration noise may become relatively more attractive over the next 1-2 quarters. Conversely, any competitor with overlapping rare-disease assets could face pressure if investors start to reward scale and pipeline depth over narrow single-product narratives.

The key catalyst/risk is not the reported quarter; it is the next two guidance checkpoints. If the company can translate this into visible operating leverage by the next print, the stock can re-rate higher even without another major beat. If margin optics stay messy or the incremental guidance is seen as acquisition-driven rather than self-generated, the high multiple becomes the anchor and downside can reassert quickly on any market-wide biotech risk-off move.

Consensus appears to be underestimating how much of the move is sentiment-driven versus fundamental. The spread in analyst targets implies this is still a narrative stock, and those names tend to overshoot in both directions when revisions and valuation collide. That makes the asymmetry more attractive on a relative basis than outright: the business can look fine while the stock remains vulnerable to multiple compression unless management re-establishes a cleaner earnings bridge.

Key Decisions for Investors

• Initiate a relative-value long BMRN / short a basket of slower-growth large-cap biotech over the next 1-3 months; expect BMRN to outperform if the market rewards revenue visibility and rare-disease scarcity, but cap the position if margin noise persists.
• Sell downside puts in BMRN 1-2 earnings cycles out only if implied volatility remains elevated; the thesis is that post-print de-risking can monetize rich vol while retaining upside if guidance is validated.
• If already long BMRN, trim 20-30% into strength and hold a core position through the next guidance update; the risk/reward is skewed to range-bound trading until operating leverage becomes clearer.
• For a more defensive expression, pair long BMRN with short a higher-beta, pre-profit biotech name for 2-4 months; this isolates quality-guidance upside while reducing sector drawdown risk.
• Set a tactical stop if BMRN fails to hold post-print support over the next 2-3 weeks; a break would signal the market is treating the revenue beat as non-recurring and the multiple could compress further.